Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 10, 2013, Pages

  Dreier, Birgit ^a   Honegger, Annemarie ^a   Hess, Christian ^a   Nagy Davidescu, Gabriela ^a   Mittl, Peer R E ^a   Grütter, Markus G ^a   Belousova, Natalya ^b   Mikheeva, Galina ^b   Krasnykh, Victor ^b   Plückthun, Andreas ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Protein design; Protein engineering; Tumor targeting; Viral retargeting; X ray crystallography

Indexed keywords

ANKYRIN; CAPSID PROTEIN; DESIGNED ANKYRIN REPEAT PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; UNCLASSIFIED DRUG;

ADENOVIRUS; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; CRYSTAL STRUCTURE; ESCHERICHIA COLI; KINETICS; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRUSES, HUMAN; ANKYRIN REPEAT; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; ESCHERICHIA COLI; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HEK293 CELLS; HUMANS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN STRUCTURE, QUATERNARY; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS;

EID: 84874592972     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1213653110     Document Type: Article

References (75)

1. Amalfitano A, Parks RJ (2002) Separating fact from fiction: Assessing the potential of modified adenovirus vectors for use in human gene therapy. Curr Gene Ther 2(2): 111-133.
2. Edelstein ML, Abedi MR, Wixon J (2007) Gene therapy clinical trials worldwide to 2007-an update. J Gene Med 9(10):833-842.
3. Verma IM, Weitzman MD (2005) Gene therapy: Twenty-first century medicine. Annu Rev Biochem 74:711-738.
4. Bergelson JM, et al. (1997) Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275(5304):1320-1323.
5. Tomko RP, Xu R, Philipson L (1997) HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 94(7):3352-3356.
6. Arnberg N, Edlund K, Kidd AH, Wadell G (2000) Adenovirus type 37 uses sialic acid as a cellular receptor. J Virol 74(1):42-48.
7. Gaggar A, Shayakhmetov DM, Lieber A (2003) CD46 is a cellular receptor for group B adenoviruses. Nat Med 9(11):1408-1412.
8. Short JJ, et al. (2004) Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology 322(2):349-359.
9. Wang H, et al. (2011) Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med 17(1):96-104.
10. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR (1993) Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment. Cell 73(2):309-319.
11. Nemerow GR, Pache L, Reddy V, Stewart PL (2009) Insights into adenovirus host cell interactions from structural studies. Virology 384(2):380-388.
12. Russell WC (2009) Adenoviruses: Update on structure and function. J Gen Virol 90(Pt 1):1-20.
13. Alba R, et al. (2009) Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: Effect of mutagenesis on FX interactions and gene transfer. Blood 114(5):965-971.
14. Khare R, Chen CY, Weaver EA, Barry MA (2011) Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther 11(4):241-258.
15. Koizumi N, et al. (2006) Modified adenoviral vectors ablated for coxsackievirusadenovirus receptor, αv integrin, and heparan sulfate binding reduce in vivo tissue transduction and toxicity. Hum Gene Ther 17(3):264-279.
16. Krasnykh VN, Douglas JT, van Beusechem VW (2000) Genetic targeting of adenoviral vectors. Mol Ther 1(5 Pt 1):391-405.
17. Nicklin SA, Wu E, Nemerow GR, Baker AH (2005) The influence of adenovirus fiber structure and function on vector development for gene therapy. Mol Ther 12(3): 384-393.
18. Noureddini SC, Curiel DT (2005) Genetic targeting strategies for adenovirus. Mol Pharm 2(5):341-347.
19. Coughlan L, et al. (2010) Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses 2(10):2290-2355.
20. Philipson L, Pettersson RF (2004) The coxsackie-adenovirus receptor-a new receptor in the immunoglobulin family involved in cell adhesion. Curr Top Microbiol Immunol 273:87-111.
21. Belousova N, et al. (2003) Genetically targeted adenovirus vector directed to CD40- expressing cells. J Virol 77(21):11367-11377.
22. Belousova N, Mikheeva G, Gelovani J, Krasnykh V (2008) Modification of adenovirus capsid with a designed protein ligand yields a gene vector targeted to a major molecular marker of cancer. J Virol 82(2):630-637.
23. Krasnykh VN, Mikheeva GV, Douglas JT, Curiel DT (1996) Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 70(10): 6839-6846.
24. Wickham TJ, et al. (1997) Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 71(11):8221-8229.
25. Magnusson MK, et al. (2012) A transductionally retargeted adenoviral vector for virotherapy of Her2/neu-expressing prostate cancer. Hum Gene Ther 23(1):70-82.
26. Waehler R, Russell SJ, Curiel DT (2007) Engineering targeted viral vectors for gene therapy. Nat Rev Genet 8(8):573-587.
27. Chen CY, May SM, Barry MA (2010) Targeting adenoviruses with factor x-single-chain antibody fusion proteins. Hum Gene Ther 21(6):739-749.
28. Dmitriev I, Kashentseva E, Rogers BE, Krasnykh V, Curiel DT (2000) Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J Virol 74(15):6875-6884.
29. Ebbinghaus C, et al. (2001) Functional and selective targeting of adenovirus to highaffinity Fcgamma receptor I-positive cells by using a bispecific hybrid adapter. J Virol 75(1):480-489.
30. Haisma HJ, et al. (2010) Selective targeting of adenovirus to αvβ3 integrins, VEGFR2 and Tie2 endothelial receptors by angio-adenobodies. Int J Pharm 391(1-2):155-161.
31. Hong SS, Galaup A, Peytavi R, Chazal N, Boulanger P (1999) Enhancement of adenovirus-mediated gene delivery by use of an oligopeptide with dual binding specificity. Hum Gene Ther 10(16):2577-2586.
32. Korokhov N, et al. (2003) Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge. J Virol 77(24):12931-12940.
33. Pereboev AV, et al. (2004) Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule. Mol Ther 9(5):712-720.
34. Reynolds PN, et al. (2000) A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Mol Ther 2(6):562-578.
35. Watkins SJ, Mesyanzhinov VV, Kurochkina LP, Hawkins RE (1997) The 'adenobody' approach to viral targeting: Specific and enhanced adenoviral gene delivery. Gene Ther 4(10):1004-1012.
36. Wickham TJ, et al. (1996) Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol 70(10):6831-6838.
37. Dreier B, et al. (2011) Her2-specific multivalent adapters confer designed tropism to adenovirus for gene targeting. J Mol Biol 405(2):410-426.
38. Zlotnick A, Stray SJ (2003) How does your virus grow? Understanding and interfering with virus assembly. Trends Biotechnol 21(12):536-542.
39. Kirby I, et al. (1999) Mutations in the DG loop of adenovirus type 5 fiber knob protein abolish high-affinity binding to its cellular receptor CAR. J Virol 73(11):9508-9514.
40. Roelvink PW, Mi Lee G, Einfeld DA, Kovesdi I, Wickham TJ (1999) Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science 286(5444):1568-1571.
41. Wetzel SK, et al. (2010) Residue-resolved stability of full-consensus ankyrin repeat proteins probed by NMR. J Mol Biol 402(1):241-258.
42. Wetzel SK, Settanni G, Kenig M, Binz HK, Plückthun A (2008) Folding and unfolding mechanism of highly stable full-consensus ankyrin repeat proteins. J Mol Biol 376(1): 241-257.
43. Forrer P, Chang C, Ott D, Wlodawer A, Plückthun A (2004) Kinetic stability and crystal structure of the viral capsid protein SHP. J Mol Biol 344(1):179-193.
44. Steiner D, Forrer P, Plückthun A (2008) Efficient selection of DARPins with subnanomolar affinities using SRP phage display. J Mol Biol 382(5):1211-1227.
45. Zahnd C, et al. (2007) A designed ankyrin repeat protein evolved to picomolar affinity to Her2. J Mol Biol 369(4):1015-1028.
46. Binz HK, Stumpp MT, Forrer P, Amstutz P, Plückthun A (2003) Designing repeat proteins: Well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J Mol Biol 332(2):489-503.
47. Bewley MC, Springer K, Zhang YB, Freimuth P, Flanagan JM (1999) Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR. Science 286(5444):1579-1583.
48. Gensler M, Buschbeck M, Ullrich A (2004) Negative regulation of HER2 signaling by the PEST-type protein-tyrosine phosphatase BDP1. J Biol Chem 279(13):12110-12116.
49. Belousova N, et al. (2010) Development of a targeted gene vector platform based on simian adenovirus serotype 24. J Virol 84(19):10087-10101.
50. Boersma YL, Chao G, Steiner D, Wittrup KD, Plückthun A (2011) Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling. J Biol Chem 286(48):41273-41285.
51. Stefan N, et al. (2011) DARPins recognizing the tumor-associated antigen EpCAM selected by phage and ribosome display and engineered for multivalency. J Mol Biol 413(4):826-843.
52. Simon M, Zangemeister-Wittke U, Plückthun A (2012) Facile double-functionalization of designed ankyrin repeat proteins using click and thiol chemistries. Bioconjug Chem 23(2):279-286.
53. Kirby I, et al. (2000) Identification of contact residues and definition of the CARbinding site of adenovirus type 5 fiber protein. J Virol 74(6):2804-2813.
54. Kashentseva EA, Seki T, Curiel DT, Dmitriev IP (2002) Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain. Cancer Res 62(2):609-616.
55. Kim J, et al. (2002) Targeting adenoviral vectors by using the extracellular domain of the coxsackie-adenovirus receptor: Improved potency via trimerization. J Virol 76(4): 1892-1903.
56. Alba R, et al. (2010) Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood 116(15):2656-2664.
57. Binz HK, et al. (2004) High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol 22(5):575-582.
58. Boersma YL, Plückthun A (2011) DARPins and other repeat protein scaffolds: Advances in engineering and applications. Curr Opin Biotechnol 22(6):849-857.
59. Dreier B, Plückthun A (2012) Rapid selection of high-affinity binders using ribosome display. Methods Mol Biol 805:261-286.
60. Hanes J, Jermutus L, Weber-Bornhauser S, Bosshard HR, Plückthun A (1998) Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries. Proc Natl Acad Sci USA 95(24):14130-14135.
61. Hanes J, Plückthun A (1997) In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci USA 94(10):4937-4942.
62. Plückthun A (2012) Ribosome display: A perspective. Methods Mol Biol 805:3-28.
63. Tamaskovic R, Simon M, Stefan N, Schwill M, Plückthun A (2012) Designed ankyrin repeat proteins (DARPins) from research to therapy. Methods Enzymol 503:101-134.
64. Zahnd C, Amstutz P, Plückthun A (2007) Ribosome display: Selecting and evolving proteins in vitro that specifically bind to a target. Nat Methods 4(3):269-279.
65. Martin-Killias P, Stefan N, Rothschild S, Plückthun A, Zangemeister-Wittke U (2011) A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity. Clin Cancer Res 17(1):100-110.
66. Theurillat JP, et al. (2010) Designed ankyrin repeat proteins: A novel tool for testing epidermal growth factor receptor 2 expression in breast cancer. Mod Pathol 23(9): 1289-1297.
67. Zahnd C, et al. (2010) Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: Effects of affinity and molecular size. Cancer Res 70(4):1595-1605.
68. Xu Z, Tian J, Smith JS, Byrnes AP (2008) Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J Virol 82(23): 11705-11713.
69. Kalyuzhniy O, et al. (2008) Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci USA 105(14):5483-5488.
70. Waddington SN, et al. (2008) Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132(3):397-409.
71. Roberts DM, et al. (2006) Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441(7090):239-243.
72. Chartier C, et al. (1996) Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 70(7):4805-4810.
73. Mohanty S, et al. (2005) Overexpression of IRS2 in isolated pancreatic islets causes proliferation and protects human beta-cells from hyperglycemia-induced apoptosis. Exp Cell Res 303(1):68-78.
74. Becker TC, et al. (1994) Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol 43(Pt A):161-189.
75. Mittereder N, March KL, Trapnell BC (1996) Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 70(11):7498-7509.